New Imaging Workstation Provides Superior Sensitivity for Gel/Blot Analyses
|
By LabMedica International staff writers Posted on 08 Jan 2013 |

Image: The PXi Multiapplication gel and blot imaging system (Photo courtesy of Syngene).
A new high resolution, multiapplication imaging system includes a wide range of lighting options, a new-generation camera, and specialized software, enabling exceptional sensitivity for analysis of gels and blots.
The PXi gel and blot imaging system from Syngene (Frederick, MD, USA) is a sophisticated and easy-to-use, compact workstation for the capture and image analysis of chemiluminescent and fluorescent blots, fluorescent and IR gels, visible gels and blots, and even 2D gels. PXi is available in three versions - with a 4, 6, or 8 million pixel high performance camera and suitable lens that results in the system having superior sensitivity such that even faint gels, chemiluminescence blots, and faint fluorescent bands can be imaged. In addition, the cameras are cooled to enable longer exposures, which can be a necessity for chemiluminescence and for some fluorescence applications.
The high performance range of PXi has been designed to provide a high level of control and to excel at a wide range of applications. The system has options for advanced automation or manual control. A number of lighting options can be utilized including plug and play LED modules for Red, Green, Blue and IR light. These novel lighting systems provides the user with the ability to perform colored fluorescent, multiplex, and colorimetric imaging. The new UltraSlim blue LED transilluminator provides a solution for imaging “safe dyes.” An integral 7-position filter wheel can accommodate a wide range of Syngene filters. PXi is controlled by the GeneSys acquisition and capture software. Using its database, GeneSys can automatically configure PXi to capture any type of image.
Related Links:
Syngene
The PXi gel and blot imaging system from Syngene (Frederick, MD, USA) is a sophisticated and easy-to-use, compact workstation for the capture and image analysis of chemiluminescent and fluorescent blots, fluorescent and IR gels, visible gels and blots, and even 2D gels. PXi is available in three versions - with a 4, 6, or 8 million pixel high performance camera and suitable lens that results in the system having superior sensitivity such that even faint gels, chemiluminescence blots, and faint fluorescent bands can be imaged. In addition, the cameras are cooled to enable longer exposures, which can be a necessity for chemiluminescence and for some fluorescence applications.
The high performance range of PXi has been designed to provide a high level of control and to excel at a wide range of applications. The system has options for advanced automation or manual control. A number of lighting options can be utilized including plug and play LED modules for Red, Green, Blue and IR light. These novel lighting systems provides the user with the ability to perform colored fluorescent, multiplex, and colorimetric imaging. The new UltraSlim blue LED transilluminator provides a solution for imaging “safe dyes.” An integral 7-position filter wheel can accommodate a wide range of Syngene filters. PXi is controlled by the GeneSys acquisition and capture software. Using its database, GeneSys can automatically configure PXi to capture any type of image.
Related Links:
Syngene
Latest BioResearch News
- Single-Cell Method Measures RNA and Proteins to Reveal Immune Responses
- Study Links Midlife Vitamin D to Lower Tau in Alzheimer's
- International Consensus Standardizes Tumor Microbiota Detection and Reporting
- Common Metablolic Enzyme Could Predict Response to Cancer Immunotherapy
- Newly Identfied Genetic Variants in MND Support Prognosis and Family Testing
- Innate Immunity Variants Associated With Earlier Breast Cancer in BRCA1 Carriers
- Genetic Cause Identified for Severe Infant Epilepsy
- Study Reveals Diagnostic and Therapeutic Target in Rare Pancreatic Tumors
- Researchers Identify Survival Pathway Undermining Targeted Cancer Drugs
- Large-Scale Study Maps DNA Damage Signatures Across Multiple Cancers
- Study Identifies Distinct Immune Signatures to Early Depression and Psychosis
- Genetic Mutation Behind Aggressive Adult Leukemia Offers Treatment Clues
- Disease Gene Discovery Advances Diagnosis of Rare Movement Disorders
- Genetic Discovery Could Improve Diagnosis of Drug-Resistant Epilepsy
- Genetic Discovery May Improve Diagnosis of Rare Dementia Subtype
- Mass Spectrometry Technique Detects Protein and Sugar Changes in Neurodegeneration
Channels
Clinical Chemistry
view channel
AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
Cardiovascular diseases are a leading cause of death, responsible for nearly 20 million deaths each year. Timely triage of myocardial infarction and heart failure hinges on rapid cardiac biomarker measurement,... Read moreNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read moreMolecular Diagnostics
view channel
Genome Sequencing Identifies Noncoding Variants Causing Neonatal Diabetes
Neonatal diabetes is a rare form of diabetes that presents in the first six months of life and is driven by genetic changes, yet many affected families still lack definitive diagnoses. Genetic studies... Read more
Genetic Markers Predict GLP-1 Weight-Loss Response and Side Effects
Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and tirzepatide are now widely used for weight management, yet individual responses vary considerably, with some patients experiencing... Read moreHematology
view channel
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read more
New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
Monitoring response to antiplatelet therapy remains challenging for many clinical laboratories. Aggregation-based assays and cartridge systems often require specialized personnel, dedicated instruments,... Read moreImmunology
view channelCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
Intensive care units face persistent threats from hospital-acquired infections, increasingly driven by drug-resistant bacteria. Rapidly pinpointing environmental reservoirs and transmission hotspots remains... Read more
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read morePathology
view channelAI Improves Completeness of Complex Cancer Pathology Reports
Oncology teams increasingly rely on pathology reports that integrate histopathology, immunohistochemistry, and rapidly expanding biomarker testing. As patients live longer and undergo repeated analyses... Read more
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreTechnology
view channel
Noninvasive Sputum Test Detects Early Lung Cancer
Early detection remains critical for improving outcomes in lung cancer, yet clinicians increasingly encounter indeterminate pulmonary nodules found incidentally or through screening, complicating decision-making.... Read more
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR
GRAIL’s Galleri multi-cancer early detection (MCED) test is being integrated into Epic’s electronic health record (EHR) platform through Epic Aura. The collaboration is designed to let clinicians at interested... Read moreGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more







